NOTICE: Due to a lapse in annual appropriations, most of this website is not being updated. Learn more.
Form submissions will still be accepted but will not receive responses at this time. Sections of this site for programs using non-appropriated funds (such as NVLAP) or those that are excepted from the shutdown (such as CHIPS and NVD) will continue to be updated.
An official website of the United States government
Here’s how you know
Official websites use .gov
A .gov website belongs to an official government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you’ve safely connected to the .gov website. Share sensitive information only on official, secure websites.
Peptide Valency Plays an Important Role in the Activity of a Synthetic Fibrin-Crosslinking Polymer
Published
Author(s)
Robert J. Lamm, Esther B. Lim, Kathleen Weigandt, Lilo D. Pozzo, Nathan J. White, Suzie H. Pun
Abstract
Therapeutic polymers have the potential to improve the standard of care for hemorrhage, or uncontrolled bleeding, as synthetic hemostats. PolySTAT, a fibrin-crosslinking peptide-polymer conjugate, has the capacity to rescue fibrin clot formation and improve survival in a model of acute traumatic bleeding. PolySTAT consists of a synthetic polymer backbone to which targeting fibrin-binding peptides are linked. For translation of PolySTAT, the optimal valency of peptides must be determined. Grafting of fibrin-binding peptides to the poly(hydroxyethyl methacrylate)-based backbone was controlled to produce peptide valences ranging from 0 to 10 peptides per polymer. PolySTATs with valencies of 4 or greater resulted in increased clot firmness, kinetics, and decreased breakdown as measured by thromboelastometry. A valency of 4 increased clot firmness 57% and decreased clot breakdown 69% compared to PBS. This trend was characterized by neutron scattering, which probed the structure of clots formed in the presence of PolySTAT. Finally, PolySTAT with valencies of 4 (100% survival; p = 0.013) and 8 (80% survival; p = 0.063) improved survival compared to an albumin control in a femoral artery injury model (20% survival). This work demonstrates tunability of hemostatic polymers and the ability of in vitro assays to predict i}in vivo efficacy.
Lamm, R.
, Lim, E.
, Weigandt, K.
, Pozzo, L.
, White, N.
and Pun, S.
(2017),
Peptide Valency Plays an Important Role in the Activity of a Synthetic Fibrin-Crosslinking Polymer, Biomaterials, [online], https://tsapps.nist.gov/publication/get_pdf.cfm?pub_id=922628
(Accessed October 8, 2025)